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Abstract
Testicular cancer (TC) as well as malignant lymphoma (ML), both have nowadays an excellent prognosis. However, both types of cancer
may be diagnosed at young adulthood and patients may experience sexual concerns. In this article the need for information and support
concerning sexuality will be explored, and the traumatic impact of cancer diagnosis with respect to this will be considered. A total of 264
patients with testicular cancer, median age 36 (S.D. 9.7) years, and 50 patients with malignant lymphoma, median age 42 (S.D. 11.7) years
returned a questionnaire concerning sexual functioning; four items assessed the need for information or support concerning sexuality, at
diagnosis and at follow-up. It appeared that more than half of the patients with testicular cancer reported a lack of information and support
concerning sexuality during treatment; 67% of them still had a need for information at follow-up. These rates were significantly lower for
patients with malignant lymphoma. Especially patients with testicular cancer who suffered sexual dysfunction reported extremely high needs
for information and support. According to these findings it can be concluded that more attention should be paid to the doctor–patient
communication with respect to sexual concerns in general, and especially where it concerns patients with testicular cancer.
# 2003 Published by Elsevier Science Ireland Ltd.
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1. Introduction
An increasing number of patients with cancer has a
favourable long-term prognosis with the aid of well-defined
treatment modalities. Since two decades almost 90% of the
patients treated for testicular cancer can be cured [1].
However, patients may experience considerable psychoso-
cial and existential burden, some of them until many years
after the initial treatment (see for example [2–6]). There are
several reasons why this type of cancer, although in many
cases ‘curable’, may be experienced as an invasive emo-
tional event. First, testicular cancer affects young men in
their prime of life (diagnostic age 15–35 years) [7,8]; they
are very unexpectedly confronted with a life-threatening
diagnosis. Second, patients have to face problems that one
expects at old age, not at young age. Third, in case of
metastases the polychemotherapy (and surgery) may be
experienced as very invasive; the treatment itself may
provoke death-anxiety [9,10]. Fourth, all patients will have
to cope with the risk and fear of recurrence, so with a diffuse
image of the future for many years [11]. Experiences of this
intensity may cause symptoms of post-traumatic stress [12],
including re-experiencing and/or avoiding disease-related
situations and cues, and symptoms of hyper-vigilance [13].
Only recently investigators have paid attention to post-
traumatic stress in cancer survivors and/or their relatives
[14–16]. One may assume that the impact of testicular
cancer, although the prognosis is positive, is comparable
to other types of cancer. However, a special issue in testi-
cular cancer is that it concerns the genitals. The affected
testicle will always be removed and the diagnosis signifies a
sudden and major threat from and to the male genital area.
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This may affect in especially the sexual-masculine integrity
of the person [17–23]. As a result sexual functioning can
assumed to be under pressure, and research indeed revealed
sexual morbidity among patients treated for testicular cancer
(see for example [24–26]).
In the current study we assessed the need for information
or support concerning ‘sexual functioning after treatment’ of
patients with testicular cancer, during treatment and at
follow-up, by means of a questionnaire [26]. We expected
that these needs would be higher for patients with testicular
cancer than for male patients with a non-genital tumour.
Therefore the questionnaire was also sent to a sample of
male patients with a non-genital tumour, in case malignant
lymphoma.
Outcomes were related to reported changes in sexual
functioning, as well as to age and duration of follow-up. If
it is true that testicular cancer, being a genital tumour,
triggers a sexual uncertainty we hypothesise that:
(a) Informational as well as supportive needs concerning
sexuality will be prominent, in especially in patients
with testicular cancer;
(b) These needs will have a relatively low correlation with
the actual sexual functioning as such, and;
(c) Assuming the sexual-traumatic impact of testicular
cancer, these needs will be relatively stable and not
strongly related to duration of follow-up.
2. Methods
2.1. Patients and treatments
The medical records of (male) patients, treated since 1977
at the University Medical Center Groningen (UMCG) for a
malignant testicular germ cell tumour (TC), or for malignant
lymphoma (ML), were checked concerning their health
status. Since 1977 the treatment of cancer improved dra-
matically due to the application of cisplatin-based che-
motherapy [27]. Patients who were alive, without signs of
recurrence, aged between 17–70 years, were sent a ques-
tionnaire. The age boundary of 70 years was chosen because
it may prevent bias, due to the risk of including patients with
physical or mental co-morbidity, or bereavement due to old
age. Patients were informed by a covering letter about the
aim of the study and the use of the data; it was emphasised
that non-response would in no way affect treatment. Permis-
sion to conduct this study was obtained from the Medical
Ethical Committee of the UMCG.
Testicular cancer (TC): all patients with TC are orchi-
dectomized. TC consists of two subtypes: seminoma and
non-seminoma germ cell tumours. Dependent on dissemi-
nation grade the tumours are classified in stages I (no
dissemination outside the testicles) to IV (dissemination
outside the lymph nodes, such as lung metastases). Semi-
noma tumours are always treated with RT. Non-seminoma
tumours are, dependent on stage, treated with a ‘wait & see
policy’ (W&S, stage I) or polychemotherapy (PCT, stage II–
IV). If there is any residual retro-peritoneal tumour mass,
surgical resection follows subsequently (PCTþ surgery
[1,28]).
Malignant lymphoma also consists of two subtypes:
Hodgkin’s disease (HD), treated with RT (stages I–IIA),
or PCT (all other stages); and non-Hodgkin lymphoma
(NHL), treated only with PCT (dependent on stage: three
courses combined with involved field radiotherapy 30–
40 Gy for stage I; six to eight courses for stages II–IV
[29,30]. Generally, age-effects have to be considered,
because the age at diagnosis in case of non-Hodgkin lym-
phoma generally is higher (between 50 and 75 years) than in
Hodgkin’s disease (15–45 years). Age at diagnosis of a
seminoma testicular germ cell tumour generally is also about
10 years higher (between 40 and 50 years) compared to the
diagnostic age of patients with a non-seminoma tumour (20
and 35 years).
2.2. Questionnaire
To explore sexual functioning after treatment for testi-
cular cancer, we adapted a questionnaire which had been
formerly used in a explorative study among women with
gynaecological tumours [31] (see also [32]). We added four
items concerning information and support: two items were
about information and support received from the medical
staff during the treatment period (sufficient—not sufficient,
4-point scale), the two other questions assessed the current
need for information or support (yes or no).
2.3. Design
First, we wanted to assess the patients’ retrospective need
for information (in the tables abbreviated as IR: information
need retrospective) and support (SR: supportive need retro-
spective), as well as their current needs (IF: information
need at follow-up, and SF: supportive need at follow-up),
and compare the results of patients with TC to those of
patients with ML. Second, we wanted to investigate the
relationship between reported needs for information or
support and reported sexual functioning, and again compare
both patient groups (TC versus ML). Third, we wanted to
assess eventual associations between needs for information
or support at the one hand, and duration of follow-up period
and age at the other (detailed data concerning sexual func-
tioning of the testicular cancer patients were described
earlier [26]). To complete the results we checked eventual
differences between treatment sub-groups of both patient
groups.
2.4. Statistical analysis
Results concerning needs for information and support in
retrospect and at follow-up will be presented as raw scores
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(Table 1), or as dichotomised scores (cut-off half way the 0–
3-point scale, Tables 2–4). Sexual dysfunction scores were
dichotomised and a sum-index (sum-SDF) was obtained by
summing up the number of patients that reported strong/
moderate decrease of at least one (or more than one) of the
following sexual functions: libido, arousal, erection and
orgasm. This resulted in two sub-groups: patients with no
sexual dysfunction (SDF ¼ 0), patients who reported one or
more than one sexual dysfunction (SDF ¼ 14). To analyse
the differences between groups, Kruskall–Wallis’ or Mann–
Whitney’s U-test were used for categorical variables. Sig-
nificance of correlation was established by using Spearman’s
rho. A P < 0:05 was considered to be significant.
3. Results
3.1. Response and patient characteristics
 Testicular cancer: a total of 287 patients returned the
questionnaire (response rate 85% of a sample of 337
patients). Those who had incomplete medical data
(n ¼ 9), had no standard treatment (n ¼ 5) and bilateral
testicular cancer patients (n ¼ 9) were excluded. A total
of 264 patients (78% of the original sample) remained
for analysis. For treatment characteristics, see Table 4a.
Table 1
Need for information and support concerning sexuality, during treatment (retrospective) and at follow-up of patients with testicular cancer (n ¼ 264) or
malignant lymphoma (n ¼ 50)
During treatment
(retrospective)
Absolutely insufficient Insufficient Hardly sufficient Sufficient P-value
n (%) n (%) n (%) n (%) (w2)
Information (IR) TC (n ¼ 263)a 77 (29.5) 62 (23.5) 38 (14.5) 86 (32.5)
ML (n ¼ 48)a 8 (16.5) 9 (19) 7 (14.5) 24 (50) NS
Support (SR) TC (n ¼ 258) 91 (35.5) 48 (18.5) 46 (18) 73 (28)
ML (n ¼ 47) 9 (19) 9 (19) 6 (13) 23 (50) 0.028
At follow-up Yes No
Need for information (IF) TC (n ¼ 262) 175 (67) 87 (33) 0.000
ML (n ¼ 48) 13 (27) 35 (73)
Need for support (SF) TC (n ¼ 262) 56 (21.5) 206 (78.5) 0.031
ML (n ¼ 49) 4 (8) 45 (92)
a Lower numbers in the table are due to missing values (this applies also to the other tables).
Table 2
Sexual dysfunction of patients with testicular cancer (n ¼ 264) and of
patients with malignant lymphoma (n ¼ 50)
Sexual dysfunction Testicular cancer Malignant lymphoma
100% (n ¼ 264) 100% (n ¼ 50)
Desire decreased % (n) 19 (51) 20.4 (10)
Arousal decreased % (n) 12 (32) 16.7 (8)
Erection decreased % (n) 12.5 (33) 16.3 (8)
Orgasm decreased % (n) 19 (50) 22.9 (11)
Sum (SDF ¼ 1–4) 29 (77) 30 (14)
Table 3













SDF ¼ 0 TC: 182 (70.5%) TC: 90 (50%) TC: 87 (48.5%) TC: 112 (61.5%) TC: 27 (15%)
ML: 33 (70%) ML: 15 (47%) ML: 19 (61.5%) ML: 7 (22%) ML: 1 (3%)
SDF ¼ 1–4 TC: 77 (29.5%) TC: 47 (61%) TC: 51 (67%) TC: 60 (78%) TC: 28 (36.5%)
ML: 14 (30%) ML: 6 (43%) ML: 9 (64.5%) ML: 5 (35.5%) ML: 3 (21.4%)
Total TC: n ¼ 261 TC: 137 (53%)a TC: 138 (54%)b TC: 172 66.5%)c TC: 55 (21%)d
ML: n ¼ 47 ML: 21 (46%) ML: 28 (62%) ML: 12 (26%) ML: 4 (8.5%)e
In ML the remaining variables reveal no significant differences between SDF ¼ 0 and SDF ¼ 14.
a Pearson’s w2; P ¼ 0:053.
b Pearson’s w2; P < 0:004.
c Pearson’s w2; P < 0:007.
d Pearson’s w2; P < 0:000.
e Pearson’s w2; P < 0:039.
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At the time of diagnosis, the median age of this patient
group was 29 (S.D. 9.4) years, at follow-up 36 (9.7) years.
The median follow-up period for TC was 5.9 (S.D. 4.4)
years. There were no significant differences concerning
demographic variables between the four treatment groups.
 Malignant lymphoma: 58 patients (response rate 72.5% of
a sample of 80 patients) returned the questionnaire. Eight
patients were excluded: six were treated before 1977, one
patient suffered from a brain tumour, and one patient
received a non-standard combination of treatments. A
total of 50 patients (62.5% of the original sample)
remained for analysis. For treatment characteristics, see
Table 4b. The median age at diagnosis was 34.4 (S.D.
11.6) years, median age at follow-up was 42 (S.D. 11.7)
years. There were no significant differences between both
sub-groups of ML.
3.2. Need for information or support concerning
sexuality
3.2.1. Comparing testicular cancer and malignant
lymphoma
Table 1 presents the raw scores of needs for information
and support of both patient groups (TC and ML), during
treatment (retrospective) as well as at follow-up.
As can be seen patients from the table, patients with TC
generally were much more dissatisfied about information
and support concerning sexuality compared to patients with
ML. Over half of the patients with TC valued information
and support offered during treatment as absolutely not/not
sufficient, and at follow-up two-thirds of these patient
group reported a current need for information concerning
sexuality.
3.2.2. Relation between sexual dysfunction and
informational or supportive needs
Although in general the reported needs for information
and support were high, we wanted to check whether there
were differences between patients with, versus without
sexual dysfunction. First we present the outcomes of
reported sexual dysfunctions in detail (Table 2) and there-
after we present the relation between informational and
supportive needs and the total number of reported sexual
dysfunctions (SDF 1–4, Table 3).
A total of 29.5% of patients with TC and 30% of patients
with ML reported one or more sexual dysfunctions (for more
details, see [33]). Although analysis at treatment level
revealed that patients with TC, treated with PCT, reported
the highest rate of sexual dysfunction, the differences
between TC and ML concerning sexual functioning reached
no statistical significance. It is remarkable that in both
patient groups, about half of the patients without sexual
dysfunction reported a lack of information and support in
retrospect; at follow-up the need for information was still
Table 4
Comparing treatment groups: need for information and support








n ¼ 122 (45%)
(a) Testicular cancer (n ¼ 264)
During treatment
Insufficient informationa 139 (53%) 30 (52%) 17 (41.5%) 22 (52.5%) 70 (57.5%) 0.370
Insufficient supporta 139 (54%) 32 (57%) 14 (34%) 25 (59.5%) 68 (57%) 0.052
At follow-up
Need for information: ‘yes’ 175 (67%) 41 (71%) 25 (61%) 28 (67%) 81 (67%) 0.800
Need for support: ‘yes’ 56 (21.5%) 6 (10.5%) 7 (17%) 9 (21.5%) 34 (28%) 0.048
Total n (%) Treatment-groups (P-valuec)
HD-RT;
n ¼ 8 (16%)
HD-PCT;
n ¼ 18 (36%)
NHL-PCT;
n ¼ 24 (48%)
(b) Malignant lymphoma (n ¼ 50)
During treatment
Insufficient informationa 17 (35.5%) 3 (37.5%) 5 (29.5%) 9 (39%) (NS)
Insufficient supporta 18 (38%) 3 (43%) 4 (23.5%) 11 (48%) (NS)
At follow-up
Need for information: ‘yes’ 13 (27%) 1 (12.5%) 7 (41%) 5 (22%) (NS)
Need for support: ‘yes’ 4 (8%) 1 (12.5%) 3 (17%) 0 (NS)
Abbreviations: TC: testicular cancer, ML: malignant lymphoma, HD: Hodgkin’s disease, NHL: non-Hodgkin’s lymphoma, W&S: wait & see policy, RT:
radiation therapy, PCT: polychemotherapy.
a Dichotomised scores: absolute or moderate insufficient information or support.
b Pearson’s w2; P < 0:05; NS: not-significant.
c In ML statistical differences between sub-groups are hard to establish, due to low numbers per sub-group.
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very high for patients with TC. However, patients with TC
with sexual dysfunction reported significantly higher needs
for information and support compared to patients without
sexual dysfunction; for patients with ML this was only de
case concerning ‘need for support’ at follow-up. So, patients
with TC showed a stronger increase of needs for information
and support (in retrospect and at follow-up) when sexual
dysfunction was the matter than patients with ML.
3.2.3. Interrelations
Relations between informational and supportive needs:
the correlation between reported lack of information and
lack of support in retrospect was very high in TC (rho 0.78),
as well in ML (rho 0.83). This means that responses on these
two retrospective items were very similar. However, in both
patient groups there was no relationship of interest between
these two variables and duration of follow-up period, as well
as age. As the need for information and support at follow-up
concerned a dichotomous question, we compared means of
patients answering ‘yes’ versus ‘no’. Patients that did want
information at follow-up (about 30% in both patient groups),
also wanted more frequently support; while of the patients
that wanted no information at follow-up almost all also
wanted no support.
Relations of informational and supportive needs with
follow-up period and age:
 Testicular cancer: there were no differences in age
between TC patients that currently wanted information
yes versus no, or support yes versus no. But TC patients
that wanted support at follow-up had a some longer
follow-up period (mean 6.5 versus 8 years, P < 0:22).
 Malignant lymphoma: there were no differences in fol-
low-up period between ML patients that currently wanted
information yes versus no, or support yes versus no. But
ML patients that wanted information at follow-up were
relatively younger (mean 35 versus 45 years, P < 0:005).
3.2.4. Treatment-specific effects?
As mentioned in the Section 2, TC as well as ML
consisted of diverse histological and/or treatment sub-
groups. To identify treatment groups that may need special
attention, we would like to check whether there were
differences between treatment sub-groups concerning infor-
mational or supportive needs (Table 4a and b).
 Testicular cancer: patients treated with RT were signifi-
cantly less dissatisfied with support in retrospect (SR 34%
in RT, versus respectively 57% in ‘wait & see’, 59.5% in
PCT, and 57% in PCTþRRRTM, Chi P < 0:052).
Patients treated with PCTþ surgery reported the highest
need for support at follow-up (SF 28% versus respectively
10.5% in W&S, 17% in RT and 21.5% in PCT, Chi
P < 0:048); those are also the patients with the most
threatening stage, treated with the most intensive treat-
ment regimen, and reporting the highest level of sexual
dysfunction.
 Malignant lymphoma: in ML (statistical) differences
between sub-groups were hard to establish, due to low
numbers per sub-group. At face value, HD-PCT treated
patients had the lowest dissatisfaction with information
and support in retrospect, but not at follow-up.
4. Conclusion and discussion
Generally, cancer diagnosis implies loss of control in
many aspects of life. Especially carcinoma of the testicles
may result in sexual dysfunctioning. In this article we
explored the subjective need for information and support
concerning sexuality of testicular cancer patients, and com-
pared these to a group of male patients with a non-genital
tumour (malignant lymphoma). We assumed that:
(a) Informational as well as supportive needs concerning
sexuality will be prominent in both patient groups, but
higher in patients with testicular cancer.
(b) There is a relatively low association with actual sexual
functioning.
(c) Needs for information and support may remain a long
time after treatment, due to the psychological impact of
the cancer diagnosis.
In general the results underscored these three assumptions
where it concerned needs for information, but offered
important nuances concerning the patients’ current needs
for support concerning sexuality.
Generally, patients with testicular cancer reported no
more sexual dysfunction than patients treated for malignant
lymphoma. However, concerning needs for information and
support we established some interesting differences. Look-
ing back at the period of their treatment, so in retrospect, the
majority of patients with TC, and half of the patients with
ML, considered the information and support concerning
sexuality as ‘insufficient’. Patients with TC reported a sig-
nificantly higher lack of support concerning sexual matters
during their treatment, compared to patients with ML.
Although these subjective self-reports (presenting the cog-
nition of the patients) may differ from the degree of infor-
mation and support as it was actually given during treatment,
the results offer a valid indication of the patient’s perception
of this matter. At follow-up the need for information con-
cerning sexuality was extremely high for patients with TC
(67%). The need for support at follow-up was lower for both
patient groups, but still significantly higher in patients
treated for TC compared to those with ML. Our first
hypothesis could be confirmed, which may be an indication
of a higher sexual vulnerability for patients with a genital
tumour.
In accordance with expectations, the relationship between
reported sexual dysfunction and informational and suppor-
tive needs was low. Not only the majority of patients
reporting decreased sexual functions expressed a lack of
information and support during treatment, but also about
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half of the patients without any sexual morbidity in both
patient groups (TC as well as ML). However, there appeared
to be some relation of interest between reported presence of
sexual dysfunctions and the need for support at follow-up, in
both patient groups. It appeared that TC patients with one or
more sexual dysfunctions reported extremely high needs for
information and support (up to 78%), significantly more than
TC patients without sexual dysfunction; for patients with
ML this trend was also present but could not statistically be
established. So, although in general there is a high need for
information and support, especially patients who report
sexual dysfunction may actually need support.
Generally, there appeared to be no relation between
informational or supportive needs at the one hand, and
duration of follow-up period at the other, but patients with
TC with a longer follow-up period reported more need for
support after a longer follow-up period. The very high need
for information at follow-up especially in TC (67%), also in
many of the patients without any sexual morbidity (61.5%),
underscores our hypothesis that the experienced need for
information or support does not decrease in the course of
time. This adds to the idea that the impact of (testicular)
cancer, here specifically pointed at sexuality, remains long
time after diagnosis. Although older patients are assumed to
have lower needs for information [34,35] a relationship with
age could not be established for patients with TC. This again
underscores our idea that sexuality has become a vulnerable
area particularly for patients with testicular cancer, irrespec-
tive of age.
4.1. Discussion
Comparing different treatment sub-groups with TC
revealed an interesting point: patients treated by surveil-
lance, who have—from a medical point of view—an ‘opti-
mal prognosis’ and received minimal surgical treatment,
reported a need for information and support comparable to
those treated by PCT (surgery). This finding is in line with
two other studies. Arai [36] found that testicular cancer
patients under surveillance reported equal levels of morbid-
ity, but higher needs for prosthesis and the most decreased
sense of attractiveness compared to other treatment groups.
Derdiarian found that patients with a local tumour sought
more information compared to those with metastases [37].
Irradiation may be assumed to be a less intrusive treat-
ment than polychemotherapy. Although in our study testi-
cular cancer patients treated with RT reported the lowest
needs for information and support, the differences with other
treatment groups were not significant. A recent study among
TC-RT treated patients reported that most of these patients
considered information and counselling given by their
physician about the sexual consequences of therapy to be
insufficient [32]. This evokes the idea that there seems to
exist a paradoxical relationship between objective medical
status (such as stage of disease or treatment intensity) and
subjective informational needs. Therefore, when counselling
cancer patients, it may be useful to consider the impact of
cancer on sexuality, also where it concerns a good prognosis
and/or a seemingly non-intrusive treatment.
If we should have aimed to recall the information or
support actually offered during the period of treatment, of
course memory-disturbances would be a matter of concern,
as the range of follow-up periods was rather wide (0.25–17
years). However, as it concerned a retrospective study we
were not asking for the actually offered information and
support during treatment, but how the patients themselves,
perceived information and support concerning sexuality, as
an indication of the importance of the subject. Patients may
feel dissatisfied with the information offered during treat-
ment, not because no information was offered, but may be
because it was not tailored, not adequate, could not be
processed mentally and/or did not fit their emotional needs
and this also might have hampered their memory.
4.2. Conclusions
The results from this study show much dissatisfaction
about information and support concerning sexuality among
male cancer patients with testicular cancer as well as in
patients with malignant lymphoma. Interestingly, in both
patient groups the reported need for information was much
higher than the reported sexual morbidity. The actual need
for support showed some relation to reported sexual dys-
function. Generally, patients with testicular cancer reported
a much higher need for information and support as compared
to patients with malignant lymphoma. At this point some
specific conclusions can be drawn:
(a) in general (male) cancer patients appreciate it to be
asked whether they need information or support
concerning sexuality, during treatment and during
subsequent surveillance;
(b) this seems especially relevant for patients who indeed
do suffer from sexual dysfunction;
(c) and even more specifically relevant for patients with
testicular cancer.
Therefore it can be concluded that male cancer patients in
follow-up should be professionally invited by their physician
to report about their sexual functioning, and patients with
testicular cancer in particular.
Still, we do not yet know what kind of information
concerning sexuality patients would like to receive from
their physicians. From some other studies we know that
patients consider post-treatment sexuality and fertility very
important subjects and are very appeased when the oncol-
ogist initiates the subject of sexuality [38,39]. But patients
are different in their tendency to welcome or keep off
information associated with the threat of illness [40,41],
and may become non-discriminatory in gathering informa-
tion [42]. By its very nature the experience of cancer may
intensify a general need for information and emotional
support. At the one hand information is ‘never enough’,
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but at the other hand the capacity to take-in information may
be reduced [42–45]. Although patients may formulate all
kinds of informative questions, it is not always immediately
clear what the patient is searching for: medical information
about the disease, or emotional support [46,47]. When
asked, patients most of the time cannot specify what kind
of information or support they would to receive. First of all
patients seem to have a need to express a general feeling of
uncertainty and embarrassment, not pointed to sexuality
anyway: ‘‘You just don’t understand what happens to
you, you know nothing, you cannot image that it is true’’.
Furthermore, even years after treatment, patients may show
clinical signs of having experienced the impact of a psycho-
trauma: they tend to tell about their illness in bright, detailed
and fragmented memories, sometimes interrupted by a
break through of emotions [13]. So when, for example, a
patient with testicular cancer asks: ‘‘Doctor, do you think
the disease may cause sexual difficulties?’’, such a question
may not refer to a ‘cognitive’ request for a short lecture
about sexuality after cancer in the first place. It may be
an expression of a need for interpersonal support. This
ambiguity should be taken into account when assessing or
interpreting the needs of (testicular) cancer-patients.
4.3. Practice implications
At this point we would like to offer some more general
reflections. It can be concluded from this study that male
cancer patients, and patients with testicular cancer in parti-
cular, should be professionally invited by their physician to
report about their eventual sexual concerns. Still, we do not
assume that the high rate of reported insufficient information
and support concerning sexuality per se reflects the absence
of actually given information. The adequacy and efficacy of
information or support may depend more on the quality of
the doctor–patient relationship than on the content of the
information as such, in especially where it concerns the
sexual aspects of a genital, life-threatening tumour
[18,20,48]. This relationship implies not only the vulner-
ability of the patient but, as a consequence, also of the
doctor, in who’s hands the patient feels his fate has been laid
down. Also in our civilised era, for many patients in despair
‘. . . all the time the doctor’s knowledge, like a flickering
lamp, is the one dim light in the darkness’ [49]. Here
emerges an challenge for doctors: to explore their own
capacity to face the emotions of their (male) patients, in
especially where it concerns sexuality in relation to the
threat of death [47,50–52]. However, this is also a serious
point of concern, because helpers who are emotionally
empathic with patients tend to experience ‘traumatic coun-
tertransference’, which may lead to some kind of vicarious
traumatization in the helper, when he is not supported
himself by an adequate supportive system [53]. To conclude
these reflections, from this point of view the question is not
only: how to offer enough information and support, but
especially: how to do this in the right way. May be the
most important question is: what do doctors need, to be able
to give information and support in the right way.
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